Amorphous Silicon Coatings for Orthopedic Implants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical devices, such as orthopedic and dental implants, face challenges in controlling harmful high levels of reactive oxygen species (ROS) at implantation sites, which can delay or impair bone healing and attachment.
Innovation Solution
The use of devices with treated surfaces featuring amorphous silicon oxide (SiOx), amorphous silicon oxynitride (SiONx), or amorphous silicon nitride (SiNx) thin films or nanolayers, deposited via plasma-enhanced chemical vapor deposition (PECVD), which enhance bioactive and bio-osteogenic characteristics, such as bone regeneration and formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If metal implants (e.g., titanium) are used as structural materials for bone implant, then strength is improved, but healing time increases
Solution Approach 1:
The patent applies composite materials by combining metal implant substrate with amorphous silicon oxide/silicon nitride thin film coatings. The metal provides structural strength while the bioactive ceramic coating promotes rapid bone healing through osteogenic differentiation and ROS scavenging, resolving the contradiction between strength and healing time.
Solution Approach 2:
The patent applies local quality by treating only the surface of the metal implant with amorphous silicon oxide/silicon nitride thin films. The bulk metal maintains its structural properties while the surface layer provides bioactive properties that accelerate bone healing, allowing simultaneous achievement of strength and rapid healing.
2Reliability
If hydroxyapatite and calcium phosphate-based coatings are used to foster surface bone attachment, then bone attachment is improved, but thermal expansion mismatch causes resorption and delamination
Solution Approach 1:
The patent applies parameter changes by selecting amorphous silicon oxide and silicon nitride materials whose thermal expansion coefficients can be matched to the underlying metal substrate. This eliminates the thermal expansion mismatch problem that causes delamination in hydroxyapatite coatings, while maintaining reliable bone attachment.
Solution Approach 2:
The patent uses composite materials consisting of metal substrate combined with amorphous silicon oxide/silicon nitride coatings. This composite structure provides both reliable bone attachment and thermal expansion compatibility, overcoming the limitations of pure hydroxyapatite coatings.
3Strength
If conventional materials are used to support large missing bone volume, then structural support is provided, but mechanism to control high ROS levels is lacking
Solution Approach 1:
The patent applies self-service by designing the amorphous silicon oxide/silicon nitride coating to automatically scavenge ROS through the Fenton reaction mechanism. The material itself provides the antioxidant function without requiring external intervention, simultaneously providing structural support and ROS control.
Solution Approach 2:
The patent introduces amorphous silicon oxide/silicon nitride thin films as an intermediary between the metal implant and the biological environment. This intermediary layer provides both structural support and ROS scavenging capability through controlled iron ion release and Fenton reaction, protecting osteoblasts from oxidative stress.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These treated surfaces effectively reduce ROS levels by enhancing the expression of superoxide dismutase (SOD1) and other osteogenic markers, promoting rapid and stable bone attachment, healing, and regeneration.
Implementation Method 1
ROS levels must be controlled in order to promote proper fracture healing. Elevated ROS levels may be controlled by increasing available antioxidant enzyme, such as the antioxidant enzyme, superoxide dismutase (SOD1)
Implementation Method 2
The use of devices with treated surfaces featuring amorphous silicon oxide (SiOx), amorphous silicon oxynitride (SiONx), or amorphous silicon nitride (SiNx) thin films or nanolayers, deposited via plasma-enhanced chemical vapor deposition (PECVD)
Implementation Method 3
These treated surfaces effectively reduce ROS levels by enhancing the expression of superoxide dismutase (SOD1) and other osteogenic markers, promoting rapid and stable bone attachment, healing, and regeneration
Data Source
AI summary
Amorphous SiOx (SiO2), SiONx, silicon nitride (Si3N4), surface treatments are provided, on both metal (titanium) and non-metal surfaces. Amorphous silicon-film surface treatments are shown to enhance osteoblast and osteoblast progenitor cell bioactivity, including biomineral formation and osteogenic gene panel expression, as well as enhanced surface hydroxyapatite (HA) formation. A mineralized tissue interface is provided using the amorphous silicon-based surface treatments in the presence of osteoblasts, and provides improved bone cell generation/repair and improved interface for secure attachment/bonding to bone. Methods for providing PEVCD-based silicon overlays onto surfaces are provided. Methods of increasing antioxidant enzyme (e.g., superoxide dismutase) expression at a treated surface for enhanced healing are also provided. Continuous generation and release of Si4+ ion into an in vitro or in vivo environment in the presence of osteoblasts/osteoblast progenitor cells, methods of employing same for enhancing the rate of bone healing/bone regeneration, is also described.